Scarica l'app Stockscreener
1.33
1.53%
0.02
Dopo l'orario di chiusura:
1.33
Precedente Chiudi:
$1.31
Aprire:
$1.29
Volume 24 ore:
12,934
Relative Volume:
0.08
Capitalizzazione di mercato:
$38.35M
Reddito:
$40.58M
Utile/perdita netta:
$-80.65M
Rapporto P/E:
-0.3993
EPS:
-3.331
Flusso di cassa netto:
$-8.11M
1 W Prestazione:
+10.83%
1M Prestazione:
+10.83%
6M Prestazione:
-34.80%
1 anno Prestazione:
-18.40%
Intervallo 1D:
$1.29
$1.33
Intervallo di 1 settimana:
$1.17
$1.33
Portata 52W:
$1.01
$4.35
Celularity Inc Stock (CELU) Company Profile
Nome
Celularity Inc
Settore
Industria
Telefono
(908) 768-2170
Indirizzo
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.33 | 38.35M | 40.58M | -80.65M | -8.11M | -3.331 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-30 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-06 | Downgrade | Truist | Buy → Hold |
| 2022-01-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-24 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Celularity Inc Borsa (CELU) Ultime notizie
Exclusive: NexGel to acquire regenerative biomaterial portfolio from Celularity, expects to triple revenue - MSN
Barach Family Trust Secures Board Observer Role at Celularity with 9.56% Stake - TradingView
Barach Family Trust backs Celularity (CELU) with $10M notes and 9.56% stake - Stock Titan
Celularity Inc. (CELU) stock price, news, quote and history - Yahoo Finance UK
Celularity Delays Annual 10-K Filing Amid Strains - TipRanks
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity - marketscreener.com
NEXGEL delays earnings call a week to add detail on Celularity deal - Stock Titan
Market Review: Can Celularity Inc outperform in the next rallyTrade Risk Report & Expert Approved Momentum Ideas - baoquankhu1.vn
NEXGEL to pay $15 million for Celularity regenerative biomaterial portfolio - msn.com
Aug Analyst Calls: Is Celularity Inc Equity Warrant forming higher highs and higher lows2026 Major Catalysts & Fast Moving Trade Plans - baoquankhu1.vn
Death Cross: Why is Celularity Inc stock going upWeekly Market Report & Entry Point Strategy Guides - baoquankhu1.vn
Portfolio Update: Is Celularity Inc Equity Warrant a top pick in the sector2026 Fundamental Recap & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Update Recap: Will Celularity Inc Equity Warrant benefit from AI trendsQuarterly Investment Review & Free High Return Stock Watch Alerts - baoquankhu1.vn
Fund Flows: Can Celularity Inc stock outperform in a bear marketEarnings Recap Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
Gains Report: Is Celularity Inc a stock for growth or value investors - baoquankhu1.vn
NEXGEL signs agreement to acquire regenerative biomaterial portfolio - MSN
Growth Review: Can Celularity Inc sustain earnings growthMarket Movement Recap & Low Risk High Reward Ideas - baoquankhu1.vn
If You Invested $1,000 in Celularity Inc (CELU) - Stock Titan
Aug Summary: Can Celularity Inc maintain sales growth2026 Drop Watch & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Breakout Move: Can Celularity Inc outperform in the next rally2026 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Bond Watch: What is Celularity Inc Equity Warrants revenue forecastM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
NEXGEL to Pay $15 Million for Celularity Regenerative Biomaterial Portfolio - MyChesCo
Stock Report: Will Celularity Inc Equity Warrant benefit from AI trends2026 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
Targets Report: Will Celularity Inc benefit from government policy2026 AllTime Highs & Long-Term Safe Investment Ideas - baoquankhu1.vn
Celularity strikes up to $35M licensing deal for biomaterials portfolio - MSN
WBB Securities Upgrades Celularity (CELU) - MSN
CelularityFinancial Details - Crunchbase
Buyback Watch: What is Celularity Inc Equity Warrants revenue forecast2026 Update & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
NEXGEL discloses $15M upfront payment for Celularity portfolio By Investing.com - Investing.com Canada
Celularity inks $35m deal for longevity push - Longevity.Technology
NXGL Stock: NEXGEL Signs Deal to Triple Revenue and Turn Profitable With Acquisition of Six Commercial-Stage Regenerative Biomaterial Products - Barchart.com
NEXGEL discloses $15M upfront payment for Celularity portfolio - Investing.com
NEXGEL Announces $15 Million Acquisition of Regenerative Biomaterial Products from Celularity, Expected to Triple Revenue and Drive Profitability - Quiver Quantitative
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - The Manila Times
Biomaterial deal aims to triple NEXGEL sales and turn profit - Stock Titan
Inside Celularity’s bet on NEXGEL to shake up wound care biomaterials - Stock Titan
Biotechnology company Celularity Inc. (NASDAQ: CELU) recently reaffirmed its strategic commercialization partnership with NEXGEL, INC. (NASDAQ: NXGL). - Bitget
Macro Review: Is Celularity Inc Equity Warrant a speculative investmentIndex Update & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Celularity licenses biomaterials portfolio for up to $35 million By Investing.com - Investing.com Canada
Celularity licenses biomaterials portfolio for up to $35 million - Investing.com Nigeria
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products - Investing News Network
Celularity Inc. Secures $35 Million Strategic License Deal and Strengthens Capital Position to Advance Longevity-Focused Strategy - marketscreener.com
NexGel Acquires Celularity Regenerative Biomaterials in Transformative Deal - TipRanks
Celularity Licenses Biomaterials Portfolio to NexGel Partner - TipRanks
NexGel to Acquire Celularity Biomaterials Assets and Exclusive License in Deal Up to $35 Million - TradingView
Deal to triple NEXGEL (NASDAQ: NXGL) revenue and add profits - Stock Titan
Celularity Inc Azioni (CELU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):